Elevance Health (NYSE:ELV) Issues FY 2026 Earnings Guidance

Posted by Stanley Muller on Jun 11th, 2026

Elevance Health (NYSE:ELV – Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 26.750- for the period, compared to the consensus EPS estimate of 26.910. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Mizuho raised their target price on Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research report on Monday. Leerink Partners set a $364.00 target price on Elevance Health in a research report on Thursday, April 23rd. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Citigroup raised Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Finally, Bank of America raised their target price on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and an average price target of $416.11.

Read Our Latest Analysis on ELV

Elevance Health Stock Performance

Shares of ELV opened at $404.33 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The stock has a 50-day moving average of $362.40 and a 200-day moving average of $343.89. The company has a market cap of $87.81 billion, a PE ratio of 17.20, a P/E/G ratio of 2.40 and a beta of 0.67. Elevance Health has a one year low of $273.71 and a one year high of $426.98.

Elevance Health (NYSE:ELV – Get Free Report) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating the consensus estimate of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period last year, the business posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts predict that Elevance Health will post 26.94 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s payout ratio is 29.26%.

Hedge Funds Weigh In On Elevance Health

A number of hedge funds have recently added to or reduced their stakes in ELV. Pettinga Financial Advisors LLC lifted its position in shares of Elevance Health by 4.8% during the 4th quarter. Pettinga Financial Advisors LLC now owns 812 shares of the company’s stock worth $285,000 after buying an additional 37 shares in the last quarter. Foresight Global Investors Inc. lifted its position in shares of Elevance Health by 5.6% during the 4th quarter. Foresight Global Investors Inc. now owns 865 shares of the company’s stock worth $303,000 after buying an additional 46 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Elevance Health by 2.6% during the 4th quarter. UMB Bank n.a. now owns 2,113 shares of the company’s stock worth $741,000 after buying an additional 53 shares in the last quarter. HM Payson & Co. lifted its position in shares of Elevance Health by 15.0% during the 4th quarter. HM Payson & Co. now owns 437 shares of the company’s stock worth $153,000 after buying an additional 57 shares in the last quarter. Finally, CreativeOne Wealth LLC lifted its position in shares of Elevance Health by 4.4% during the 3rd quarter. CreativeOne Wealth LLC now owns 1,569 shares of the company’s stock worth $507,000 after buying an additional 66 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Company Profile

(Get Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.